PTCT vs. INCY
PTCT (PTC Therapeutics, Inc.) and INCY (Incyte Corporation) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, PTCT returned 27.78%/yr vs 3.00%/yr for INCY. Their 0.37 correlation means their historical movements had little consistent relationship.
Performance
PTCT vs. INCY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PTCT achieves a -10.47% return, which is significantly lower than INCY's 21.01% return. Over the past 10 years, PTCT has outperformed INCY with an annualized return of 27.78%, while INCY has yielded a comparatively lower 3.00% annualized return.
PTCT
- 1D
- -9.94%
- 1M
- -18.37%
- 6M
- -9.96%
- YTD
- -10.47%
- 1Y
- 30.46%
- 3Y*
- 18.70%
- 5Y*
- 12.15%
- 10Y*
- 27.78%
- ALL TIME*
- 11.78%
INCY
- 1D
- -2.82%
- 1M
- 2.28%
- 6M
- 19.44%
- YTD
- 21.01%
- 1Y
- 58.12%
- 3Y*
- 23.35%
- 5Y*
- 9.09%
- 10Y*
- 3.00%
- ALL TIME*
- 13.53%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $274.43M | $232.80M | $198.80M | |
| $107.25M | $139.40M | $141.83M |
PTCT vs. INCY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PTCT PTC Therapeutics, Inc. | -10.47% | 68.28% | 63.79% | -27.80% | -4.17% | -34.74% | 27.07% | 39.95% | 105.76% | 52.89% |
INCY Incyte Corporation | 21.01% | 43.00% | 10.00% | -21.83% | 9.43% | -15.61% | -0.39% | 37.32% | -32.86% | -5.55% |
Correlation
The correlation between PTCT and INCY is 0.35, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.35 |
Correlation (3Y) Balances recent behavior with more history. | 0.33 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.34 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.36 |
Correlation (All Time) Calculated using the full available price history since Jun 20, 2013 | 0.37 |
Fundamentals
PTCT:
$5.64B
INCY:
$24.23B
PTCT:
-$0.45
INCY:
$7.85
PTCT:
5.77
INCY:
4.22
PTCT:
$1.01B
INCY:
$5.82B
PTCT:
$476.39M
INCY:
$5.39B
PTCT:
$62.53M
INCY:
$2.04B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PTCT vs. INCY — Risk / Return Rank
PTCT
INCY
PTCT vs. INCY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for PTC Therapeutics, Inc. (PTCT) and Incyte Corporation (INCY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PTCT | INCY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.09 | ||
| Sortino ratioReturn per unit of downside risk | -1.30 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.32 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 1.13 | 3.27 | -2.14 |
| Martin ratioReturn relative to average drawdown | 2.24 | 7.23 | -5.00 |
Loading charts...
Drawdowns
PTCT vs. INCY - Drawdown Comparison
The maximum PTCT drawdown since its inception was -94.60%, roughly equal to the maximum INCY drawdown of -98.54%. Use the drawdown chart below to compare losses from any high point for PTCT and INCY.
Loading charts...
Drawdown Indicators
| PTCT | INCY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.60% | -98.54% | +3.94% |
Max Drawdown (1Y)Largest decline over 1 year | -27.17% | -18.33% | -8.84% |
Max Drawdown (3Y)Largest decline over 3 years | -56.77% | -33.83% | -22.94% |
Max Drawdown (5Y)Largest decline over 5 years | -69.42% | -40.50% | -28.92% |
Max Drawdown (10Y)Largest decline over 10 years | -73.78% | -66.47% | -7.31% |
Current DrawdownCurrent decline from peak | -24.05% | -21.71% | -2.34% |
Average DrawdownAverage peak-to-trough decline | -45.64% | -59.75% | +14.11% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.66% | 8.26% | +5.40% |
Volatility
PTCT vs. INCY - Volatility Comparison
PTC Therapeutics, Inc. (PTCT) has a higher volatility of 14.58% compared to Incyte Corporation (INCY) at 11.85%. This indicates that PTCT's price experiences larger fluctuations and is considered to be riskier than INCY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PTCT | INCY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.58% | 11.85% | +2.73% |
Volatility (6M)Calculated over the trailing 6-month period | 32.59% | 24.86% | +7.73% |
Volatility (1Y)Calculated over the trailing 1-year period | 42.99% | 33.44% | +9.55% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 55.15% | 30.10% | +25.05% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 66.20% | 34.35% | +31.85% |
Dividends
PTCT vs. INCY - Dividend Comparison
Neither PTCT nor INCY has paid dividends to shareholders.
Financials
PTCT vs. INCY - Financials Comparison
This section allows you to compare key financial metrics between PTC Therapeutics, Inc. and Incyte Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PTCT vs. INCY - Profitability Comparison
PTCT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, PTC Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 360.52M. Therefore, the gross margin over that period was 0.0%.
INCY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Incyte Corporation reported a gross profit of 1.57B and revenue of 1.67B. Therefore, the gross margin over that period was 93.7%.
PTCT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, PTC Therapeutics, Inc. reported an operating income of 148.98M and revenue of 360.52M, resulting in an operating margin of 41.3%.
INCY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Incyte Corporation reported an operating income of 697.90M and revenue of 1.67B, resulting in an operating margin of 41.7%.
PTCT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, PTC Therapeutics, Inc. reported a net income of 83.50M and revenue of 360.52M, resulting in a net margin of 23.2%.
INCY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Incyte Corporation reported a net income of 585.61M and revenue of 1.67B, resulting in a net margin of 35.0%.
Frequently Asked Questions
PTCT and INCY have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PTCT has higher volatility (14.58%) compared to INCY (11.85%). In terms of maximum drawdown, PTCT dropped -94.60% vs INCY's -98.54%.
INCY currently has the higher Sharpe Ratio (1.80 vs 0.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PTCT and INCY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer